title: Proteomics in pharmaceutical research and development.
abstract: In the 20 years since its inception, the evolution of proteomics in pharmaceutical industry has mirrored the developments within academia and indeed other industries. From initial enthusiasm and subsequent disappointment in global protein expression profiling, pharma research saw the biggest impact when relating to more focused approaches, such as those exploring the interaction between proteins and drugs. Nowadays, proteomics technologies have been integrated in many areas of pharmaceutical R&D, ranging from the analysis of therapeutic proteins to the monitoring of clinical trials. Here, we review the development of proteomics in the drug discovery process, placing it in a historical context as well as reviewing the current status in light of the contributions to this special issue, which reflect some of the diverse demands of the drug and biomarker pipelines.
authors.affiliation: Translational Technologies and Bioinformatics, Pharmaceutical Sciences, Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche AG, Basel, Switzerland.
authors.forename: Paul
authors.initials: P
authors.lastname: Cutler
authors.affiliation: Novartis Institutes for BioMedical Research, Analytical Sciences and Imaging, Basel, Switzerland.
authors.forename: Hans
authors.initials: H
authors.lastname: Voshol
mesh_terms: D000818:Animals; D055808:Drug Discovery; D004353:Drug Evaluation, Preclinical; D006801:Humans; D004364:Pharmaceutical Preparations / Q000378:metabolism*; D020543:Proteome / Q000378:metabolism; D040901:Proteomics; D012106:Research
chemical_list: D004364:Pharmaceutical Preparations; D020543:Proteome
keywords: Pharmaceutical; Proteomics; Research and development